Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc)

MLA

Overman, Michael J., et al. “Safety, Efficacy and Pharmacodynamics (PD) of MEDI9447 (Oleclumab) Alone or in Combination with Durvalumab in Advanced Colorectal Cancer (CRC) or Pancreatic Cancer (Panc).” Journal of Clinical Oncology, 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1343978708&authtype=sso&custid=ns315887.

APA

Overman, M. J., Lorusso, P., Strickler, J. H., Patel, S. P., Clarke, S. J., Noonan, A. M., Prasanna, T., Amin, M. A., Nemunaitis, J. J., Desai, J., O’Byrne, K. J., George, T. J., Englert, J., She, D., Cooper, Z. A., Wu, Y., Khan, A., Kumar, R., & Bendell, J. C. (2018). Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc). Journal of Clinical Oncology.

Chicago

Overman, Michael J., Patricia Lorusso, John H. Strickler, Sandip Pravin Patel, Stephen John Clarke, Anne M. Noonan, Thiru Prasanna, et al. 2018. “Safety, Efficacy and Pharmacodynamics (PD) of MEDI9447 (Oleclumab) Alone or in Combination with Durvalumab in Advanced Colorectal Cancer (CRC) or Pancreatic Cancer (Panc).” Journal of Clinical Oncology. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1343978708&authtype=sso&custid=ns315887.